BioNTech's investigational mRNA cancer immunotherapy BNT113, in combination with Merck's Keytruda, failed to meet its primary endpoint of progression-free survival in a Phase 2/3 clinical trial for advanced head and neck cancer. This setback led to a more than 5% drop in BioNTech's stock, as investors react to the reduced likelihood of this specific treatment's success.
BioNTech announced that its mRNA cancer immunotherapy candidate, BNT113, in combination with Merck's Keytruda, failed to achieve a statistically significant improvement in progression-free survival (PFS) in its AHEAD-MERIT Phase 2/3 clinical trial. This is a significant setback for BioNTech's oncology pipeline, as PFS is a crucial early indicator of a drug's efficacy. The stock immediately fell over 5% as investors priced in the reduced probability of this drug's success. While the trial will continue to evaluate overall survival (OS) as a second primary endpoint, the missed PFS target creates uncertainty and shifts the focus to a longer-term outcome. For traders, this represents a short-term negative catalyst for BNTX, highlighting the inherent risks in biotech clinical development.